BAYESIAN PHASE I/II ADAPTIVELY RANDOMIZED ONCOLOGY TRIALS WITH COMBINED DRUGS.
about
Approaches to modernize the combination drug development paradigmPhase I/II adaptive design for drug combination oncology trialsUsing Data Augmentation to Facilitate Conduct of Phase I-II Clinical Trials with Delayed Outcomes.A novel Bayesian seamless phase I/II design.Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic orderingAdaptive clinical trial designs in oncology.A Bayesian dose-finding design for phase I/II clinical trials with nonignorable dropoutsDose expansion cohorts in Phase I trials.A robust Bayesian dose-finding design for phase I/II clinical trials.Adaptive designs for dual-agent phase I dose-escalation studies.Adaptive phase I/II clinical trials for drug combination assessment in oncology using the outcomes of each cycle.Integrating the escalation and dose expansion studies into a unified Phase I clinical trial.Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization.A new approach to designing phase I-II cancer trials for cytotoxic chemotherapies.A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials.Implementation of a Model-Based Design in a Phase Ib Study of Combined Targeted Agents.Phase I-II clinical trial design: A state-of-the-art paradigm for dose finding.STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.Application of Bayesian hierarchical models for phase I/II clinical trials in oncology.Parametric Dose Standardization for Optimizing Two-Agent Combinations in a Phase I-II Trial with Ordinal Outcomes.Sequential monitoring of Phase I dose expansion cohorts.A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials.Analyses of drug combinations using missing data shortens trial periods in phase I/II oncology trials.
P2860
Q28072074-FB284123-C67D-4B1B-95F1-44703CBAA2FCQ30409168-422C8FE8-ACBA-419E-A9C6-D7873DB8DAC2Q30868533-3D7C4A17-669E-4276-B88B-9F0EF162334AQ34984207-A6F63C42-A711-4A46-A763-8D261AD4813AQ35175343-ACB13D17-27AD-451A-B4C9-F37295027D50Q35206844-E51C9FE0-9E13-4ADF-8984-D1B3B0EC5CDDQ35328870-96413274-DC34-442D-A5BC-78D1917678A8Q37158298-86604F77-40D4-4759-B130-6D96F8C25B12Q37220245-3A2C7239-D62B-4723-935B-FC2263582052Q38090897-DFA21DE7-3BFB-489D-8DE6-BBB3E217C0E6Q38608632-75BF6154-E250-4855-B236-7396AEF235CCQ39620076-1C6BB3CF-4795-4CE2-AA1E-0CCA0DA89648Q39910979-073B89E9-9478-4D2C-9DA2-033FFA826C17Q40415839-4A90E093-A6CD-4727-8C61-B4F6F4CCD597Q44494502-22C6484D-D5F1-42CA-8C43-FABE4CB50F43Q45063894-AF19CCE1-ACFD-4575-9A98-16371209DBE6Q47572687-F025C019-67D1-468D-8057-E47705DDD90AQ48275752-AD122F51-730E-4EF8-83FC-1D637DFAE718Q50542476-A509A46D-EED6-4EAC-8C49-55D03EB1EBE9Q52709604-63C71044-C6D5-423C-90D3-A6C86CF014D1Q54905594-2CF7C997-28AD-4251-835B-5A3CE997812DQ55069897-9DEC5175-F231-4BC2-9445-9AD6FEA8A7E4Q55306880-8696573F-3E28-4698-8845-68613D15B20C
P2860
BAYESIAN PHASE I/II ADAPTIVELY RANDOMIZED ONCOLOGY TRIALS WITH COMBINED DRUGS.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
BAYESIAN PHASE I/II ADAPTIVELY RANDOMIZED ONCOLOGY TRIALS WITH COMBINED DRUGS.
@en
type
label
BAYESIAN PHASE I/II ADAPTIVELY RANDOMIZED ONCOLOGY TRIALS WITH COMBINED DRUGS.
@en
prefLabel
BAYESIAN PHASE I/II ADAPTIVELY RANDOMIZED ONCOLOGY TRIALS WITH COMBINED DRUGS.
@en
P2860
P356
P1476
BAYESIAN PHASE I/II ADAPTIVELY RANDOMIZED ONCOLOGY TRIALS WITH COMBINED DRUGS.
@en
P2093
Guosheng Yin
P2860
P304
P356
10.1214/10-AOAS433
P577
2011-01-01T00:00:00Z